The expression of a B cell marker (CD19), pro-inflammatory cytokines (IL1B, IL6, and TNF), and CD86 (a costimulatory cell marker) in the PBMCs of 80 MS patients and 34 matched healthy controls was analyzed. This evidence concerns the gene CD19 and myeloid sarcoma.